Alligator Bioscience AB (FRA:7AL0) Risk Assessment

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Alligator Bioscience AB Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Alligator Bioscience AB is: No Data: Cannot be evaluated.

Alligator Bioscience AB  (FRA:7AL0) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Alligator Bioscience AB Risk Assessment Related Terms

FRA:7AL0 vs VRTX, REGN, RVMD: Risk Assessment Comparison

For the Biotechnology subindustry, Alligator Bioscience AB's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alligator Bioscience AB Risk Assessment vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Alligator Bioscience AB's Risk Assessment falls into.


Alligator Bioscience AB Business Description

Other Exchanges ATORX:Sweden0RK9:UK
Address Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.